Related references
Note: Only part of the references are listed.The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials
E. Segelov et al.
BRITISH JOURNAL OF CANCER (2014)
Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis
T. Asmis et al.
CURRENT ONCOLOGY (2014)
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study
Timothy J. Price et al.
LANCET ONCOLOGY (2014)
NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy
Fiona Rinaldi et al.
LANCET ONCOLOGY (2012)
Metastatic colorectal cancer: Current treatment and future options for improved survival Medical approach - present status
Bengt Glimelius et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
Delivering affordable cancer care in high-income countries
Richard Sullivan et al.
LANCET ONCOLOGY (2011)
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The continuum of care: A paradigm for the management of metastatic colorectal cancer
Richard M. Goldberg et al.
ONCOLOGIST (2007)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy, safety, and cost of new anticancer drugs
S Garattini et al.
BMJ-BRITISH MEDICAL JOURNAL (2002)
Share Paper
